Inhibitory Effects of Furanocoumarin Derivatives in Kampo Extract Medicines on P-Glycoprotein at the Blood–Brain Barrier

• Published in: Biological & Pharmaceutical Bulletin 2011/08/01, Vol.34(8), pp.1246-1251
• Main Authors: Iwanaga, Kazunori, Yoneda, Shinji, Hamahata, Yukimi, Miyazaki, Makoto, Shibano, Makio, Taniguchi, Masahiko, Baba, Kimiye, Kakemi, Masawo
• Format: Article
• Language: English
• Subjects: Animals; Apiaceae - chemistry; ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors; Biological Transport - drug effects; Blood-Brain Barrier - cytology; Blood-Brain Barrier - drug effects; Blood-Brain Barrier - metabolism; blood–brain barrier; Caco-2 Cells; Cattle; Citrus paradisi - chemistry; Coumarins - pharmacokinetics; Coumarins - pharmacology; Endothelial Cells - drug effects; Endothelial Cells - metabolism; Enzyme Inhibitors - pharmacokinetics; Enzyme Inhibitors - pharmacology; Fluoresceins - metabolism; furanocoumarin; Furans - pharmacokinetics; Furans - pharmacology; Furocoumarins - pharmacokinetics; Furocoumarins - pharmacology; Herb-Drug Interactions; Humans; inhibition; Intestinal Absorption; Kampo medicine; Male; Medicine, Kampo; P-glycoprotein; Permeability; Plant Extracts - chemistry; Plant Extracts - pharmacokinetics; Plant Extracts - pharmacology; Rats; Rats, Wistar; Rutaceae - chemistry; Verapamil - metabolism
• ISSN: 0918-6158; 1347-5215
• DOI: 10.1248/bpb.34.1246

Furanocoumarin derivatives, known as components of grapefruit juice, showing inhibitory effects against P-glycoprotein (P-gp) in the intestine are also contained in the plants of rutaceae and umbelliferae families, which are used as components of Kampo extract medicines. In this study, we investigated the inhibitory effects of byakangelicol and rivulobirin A, known as furanocoumarins showing P-gp inhibitory effect using Caco-2 monolayer, against P-gp at the blood–brain barrier (BBB) under both in vitro and in vivo conditions. First we studied the membrane permeability of furanocoumarins to clarify whether they can be absorbed from the intestine. Both furanocoumarins showed high permeability through the Caco-2 monolayer, suggesting that they can easily reach the systemic circulation after oral administration. Then, we evaluated the effect of these furanocoumarins on the uptake of calcein acetoxymethyl ester (calcein-AM), a P-gp substrate, into bovine brain microvascular endothelial cells (BBMEC). Both furanocoumarins significantly increased the uptake amount of calcein-AM into BBMEC by the inhibition of P-gp at the BBB in vitro. Next we also investigated the P-gp inhibitory effect of these furanocoumarins at the rat BBB in vivo using verapamil as a P-gp substrate. Both furanocoumarins increased the B/P ratio of verapamil compared to the control, even under in vivo conditions; however, the extent of the inhibitory effect was much lower than in vitro condition. In conclusion, byakangelicol and rivulobirin A may inhibit P-gp expressed at the BBB even under in vivo conditions. Further studies using Kampo extract medicines under in vivo condition are necessary for safe drug therapy.